Sibling Dynamics | The human side of AI, robotics, and security

The wrong question

The comparison compliance teams keep reaching for is which regulation arrives first, the EU AI Act’s extended 2027 deadline for high-risk medical devices or EMA’s 2024 reflection paper on AI across the medicinal product lifecycle. That framing overstates how settled either track is. The reflection paper is guidance issued under GxP inspection authority, not binding law, and enforcement examples remain thin in the public record. Treating it as “the standard” gets the posture right and the certainty wrong.

What EMA’s paper is, and is not

EMA’s scope claim is genuinely broad: discovery, clinical development, manufacturing, submission, and post-authorization safety surveillance are all named, alongside a human-centric approach that keeps a human accountable for AI-informed decisions. That is a real design requirement for QA teams. But a reflection paper is, by its own label, a discussion document meant to shape practice ahead of firmer rules, not a finished enforcement regime. Inspectors can reference it. They have not yet built a body of citations that tells sponsors exactly where the line sits.

FDA is running the same problem more slowly

The transatlantic comparison sharpens the picture rather than resolving it. FDA is still weighing its regulatory approach to generative AI medical devices and has floated a competency-based testing concept while actively soliciting public feedback rather than issuing settled rules. A senior FDA digital health official has said formal generative AI guidance is coming, not that it has arrived, and the considerations paper reads as a framing document, similar in kind to EMA’s reflection paper. Neither agency has finished the job. FDA is simply earlier in its own process, which the reporting on that timeline makes explicit.

Adoption is already ahead of both

The more durable fact is that AI use in regulated pipelines is not waiting on either agency. Novo Nordisk’s expanded AWS partnership for drug discovery, conference programming built around AI-driven clinical trial efficiency, and researchers using AI to reanalyze failed Alzheimer’s trial data all sit inside the lifecycle scope EMA describes, regardless of which paper eventually hardens into rule.

What this actually means for a buyer

The defensible move is not betting on which framework finalizes first. It is building a risk-tiered AI/ML QA structure, documented human review points, traceable rationale, that would satisfy either agency’s stated direction, while treating both papers as provisional. National bodies running early AI Act supervisory checks suggest inspectors are already calibrating to this kind of oversight in general, independent of which specific text they cite.

Build to the practice, not to a paper. The papers are still being written.

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The argument is internally coherent and appropriately hedged—it correctly distinguishes between guidance documents and binding law, acknowledges uncertainty on both sides of the Atlantic, and draws a
Source & Claim Verification	Qwen · local	cleared. Most factual claims are well-supported by citations, but a few lines lack specific references, such as the mention of ‘national bodies running early AI Act supervisory checks.‘
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects the provisional nature of EMA and FDA guidance but does not sufficiently address specific ISO 42001, EU AI Act, or MDR/IVDR requirements for compliance validation.
Technical Accuracy	Llama	cleared. The article accurately describes the current state of AI regulation in the pharmaceutical industry, correctly distinguishing between guidance documents and binding law, and properly characterizing the
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively identifies and counters potential vendor hype by emphasizing the provisional nature of current guidance and the lack of settled enforcement, while also acknowledging the real-
Novelty & Non-Duplication	Grok	held. Competent roundup of already-wired EMA reflection-paper and FDA genAI-discussion items, but the core ‘wrong race / build flexible QA anyway’ frame is table-stakes industry advice with no proprietary f
Validation	DeepSeek	cleared. The central claim that EMA has moved first with a substantive, albeit non-binding, position while FDA is still deliberating is validated by the provided sources and public record.